---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-008888"
form_type: "8-K"
ticker: "SILO"
cik: "0001514183"
company_name: "Silo Pharma, Inc."
filed_at: "2024-02-01T23:59:59+00:00"
generated_at: "2026-06-06T10:58:33.135714+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Silo Pharma prioritizes 2024 pipeline targeting PTSD, chronic pain, neurology; plans Pre-IND for SPC-15 by Q2

## Summary
- Lead program SPC-15 (intranasal PTSD prophylactic) Pre-IND submission planned by end of Q2 2024.
- SP-26 is a non-opioid, time-release ketamine implant for fibromyalgia, potential first at-home ketamine treatment.
- SPC-14 (Alzheimer's) positive animal results; more data expected in 2024; SPU-16 targets MS via homing peptide.
- FDA 505(b)(2) pathway to be used for SPC-15, SP-26, and SPC-14 to expedite approval and reduce costs.
- Pipeline includes four drugs across three therapeutic areas: mental health, chronic pain, and neurology.

## SEC filing metadata
- accession: 0001213900-24-008888
- form_type: 8-K
- ticker: SILO
- cik: 0001514183
- company_name: Silo Pharma, Inc.
- filed_at: 2024-02-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1514183/000121390024008888/0001213900-24-008888-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1514183/000121390024008888/ea192611-8k_silopharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-008888
- JSON: https://secwatch.observer/filing/0001213900-24-008888.json
- Plain text: https://secwatch.observer/filing/0001213900-24-008888.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.